Effect of drug sample removal on prescribing in a family practice clinic

Daniel M. Hartung, David Evans, Dean G. Haxby, Dale Kraemer, Gabriel Andeen, Lyle Fagnan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

PURPOSE Little is known about the impact of recent restrictions on pharmaceutical industry detailing and sampling on prescribing behavior, particularly within smaller, independent practices. The objective of this study was to evaluate the effect of a policy prohibiting prescription drug samples and pharmaceutical industry interaction on prescribing patterns in a rural family practice clinic in central Oregon. METHODS Segmented linear regression models were used to evaluate trends in prescribing using locally obtained pharmacy claims. Oregon Medicaid pharmacy claims were used to control for secular prescribing changes. Total and class-specific monthly trends in branded, promoted, and average prescription drug costs were analyzed 18 months before and after policy implementation. RESULTS Aggregate trends of brand name drug use did not change significantly after policy implementation. In aggregate, use of promoted agents decreased by 1.43% while nonpromoted branded agents increased by 3.04%. Branded drugs prescribed for respiratory disease declined significantly by 11.34% compared with a control group of prescribers. Relative to the control group, prescriptions of promoted cholesterol-lowering drugs and antidepressants were reduced by approximately 9.98% and 11.34%, respectively. The trend in average cost per prescription for lipid-lowering drugs was significantly reduced by $0.70 per prescription per month. Overall, average prescription drug costs increased by $5.18 immediately after policy implementation. CONCLUSIONS Restriction of pharmaceutical industry representatives and samples from a rural family practice clinic produced modest reductions in branded drug use that varied by class. Although aggregate average costs increased, prescriptions for branded and promoted lipid-lowering agents and antidepressants were reduced.

Original languageEnglish (US)
Pages (from-to)402-409
Number of pages8
JournalAnnals of Family Medicine
Volume8
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Prescription Drugs
Family Practice
Drug Industry
Prescriptions
Drug Costs
Pharmaceutical Preparations
Antidepressive Agents
Linear Models
Lipids
Costs and Cost Analysis
Control Groups
Medicaid
Names
Cholesterol

Keywords

  • Health care delivery
  • Health policy
  • Health services research

ASJC Scopus subject areas

  • Family Practice

Cite this

Effect of drug sample removal on prescribing in a family practice clinic. / Hartung, Daniel M.; Evans, David; Haxby, Dean G.; Kraemer, Dale; Andeen, Gabriel; Fagnan, Lyle.

In: Annals of Family Medicine, Vol. 8, No. 5, 09.2010, p. 402-409.

Research output: Contribution to journalArticle

Hartung, Daniel M. ; Evans, David ; Haxby, Dean G. ; Kraemer, Dale ; Andeen, Gabriel ; Fagnan, Lyle. / Effect of drug sample removal on prescribing in a family practice clinic. In: Annals of Family Medicine. 2010 ; Vol. 8, No. 5. pp. 402-409.
@article{6c86534bcef349e088874397224fcc5c,
title = "Effect of drug sample removal on prescribing in a family practice clinic",
abstract = "PURPOSE Little is known about the impact of recent restrictions on pharmaceutical industry detailing and sampling on prescribing behavior, particularly within smaller, independent practices. The objective of this study was to evaluate the effect of a policy prohibiting prescription drug samples and pharmaceutical industry interaction on prescribing patterns in a rural family practice clinic in central Oregon. METHODS Segmented linear regression models were used to evaluate trends in prescribing using locally obtained pharmacy claims. Oregon Medicaid pharmacy claims were used to control for secular prescribing changes. Total and class-specific monthly trends in branded, promoted, and average prescription drug costs were analyzed 18 months before and after policy implementation. RESULTS Aggregate trends of brand name drug use did not change significantly after policy implementation. In aggregate, use of promoted agents decreased by 1.43{\%} while nonpromoted branded agents increased by 3.04{\%}. Branded drugs prescribed for respiratory disease declined significantly by 11.34{\%} compared with a control group of prescribers. Relative to the control group, prescriptions of promoted cholesterol-lowering drugs and antidepressants were reduced by approximately 9.98{\%} and 11.34{\%}, respectively. The trend in average cost per prescription for lipid-lowering drugs was significantly reduced by $0.70 per prescription per month. Overall, average prescription drug costs increased by $5.18 immediately after policy implementation. CONCLUSIONS Restriction of pharmaceutical industry representatives and samples from a rural family practice clinic produced modest reductions in branded drug use that varied by class. Although aggregate average costs increased, prescriptions for branded and promoted lipid-lowering agents and antidepressants were reduced.",
keywords = "Health care delivery, Health policy, Health services research",
author = "Hartung, {Daniel M.} and David Evans and Haxby, {Dean G.} and Dale Kraemer and Gabriel Andeen and Lyle Fagnan",
year = "2010",
month = "9",
doi = "10.1370/afm.1135",
language = "English (US)",
volume = "8",
pages = "402--409",
journal = "Annals of Family Medicine",
issn = "1544-1709",
publisher = "Annals of Family Medicine, Inc",
number = "5",

}

TY - JOUR

T1 - Effect of drug sample removal on prescribing in a family practice clinic

AU - Hartung, Daniel M.

AU - Evans, David

AU - Haxby, Dean G.

AU - Kraemer, Dale

AU - Andeen, Gabriel

AU - Fagnan, Lyle

PY - 2010/9

Y1 - 2010/9

N2 - PURPOSE Little is known about the impact of recent restrictions on pharmaceutical industry detailing and sampling on prescribing behavior, particularly within smaller, independent practices. The objective of this study was to evaluate the effect of a policy prohibiting prescription drug samples and pharmaceutical industry interaction on prescribing patterns in a rural family practice clinic in central Oregon. METHODS Segmented linear regression models were used to evaluate trends in prescribing using locally obtained pharmacy claims. Oregon Medicaid pharmacy claims were used to control for secular prescribing changes. Total and class-specific monthly trends in branded, promoted, and average prescription drug costs were analyzed 18 months before and after policy implementation. RESULTS Aggregate trends of brand name drug use did not change significantly after policy implementation. In aggregate, use of promoted agents decreased by 1.43% while nonpromoted branded agents increased by 3.04%. Branded drugs prescribed for respiratory disease declined significantly by 11.34% compared with a control group of prescribers. Relative to the control group, prescriptions of promoted cholesterol-lowering drugs and antidepressants were reduced by approximately 9.98% and 11.34%, respectively. The trend in average cost per prescription for lipid-lowering drugs was significantly reduced by $0.70 per prescription per month. Overall, average prescription drug costs increased by $5.18 immediately after policy implementation. CONCLUSIONS Restriction of pharmaceutical industry representatives and samples from a rural family practice clinic produced modest reductions in branded drug use that varied by class. Although aggregate average costs increased, prescriptions for branded and promoted lipid-lowering agents and antidepressants were reduced.

AB - PURPOSE Little is known about the impact of recent restrictions on pharmaceutical industry detailing and sampling on prescribing behavior, particularly within smaller, independent practices. The objective of this study was to evaluate the effect of a policy prohibiting prescription drug samples and pharmaceutical industry interaction on prescribing patterns in a rural family practice clinic in central Oregon. METHODS Segmented linear regression models were used to evaluate trends in prescribing using locally obtained pharmacy claims. Oregon Medicaid pharmacy claims were used to control for secular prescribing changes. Total and class-specific monthly trends in branded, promoted, and average prescription drug costs were analyzed 18 months before and after policy implementation. RESULTS Aggregate trends of brand name drug use did not change significantly after policy implementation. In aggregate, use of promoted agents decreased by 1.43% while nonpromoted branded agents increased by 3.04%. Branded drugs prescribed for respiratory disease declined significantly by 11.34% compared with a control group of prescribers. Relative to the control group, prescriptions of promoted cholesterol-lowering drugs and antidepressants were reduced by approximately 9.98% and 11.34%, respectively. The trend in average cost per prescription for lipid-lowering drugs was significantly reduced by $0.70 per prescription per month. Overall, average prescription drug costs increased by $5.18 immediately after policy implementation. CONCLUSIONS Restriction of pharmaceutical industry representatives and samples from a rural family practice clinic produced modest reductions in branded drug use that varied by class. Although aggregate average costs increased, prescriptions for branded and promoted lipid-lowering agents and antidepressants were reduced.

KW - Health care delivery

KW - Health policy

KW - Health services research

UR - http://www.scopus.com/inward/record.url?scp=77957729105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957729105&partnerID=8YFLogxK

U2 - 10.1370/afm.1135

DO - 10.1370/afm.1135

M3 - Article

C2 - 20843881

AN - SCOPUS:77957729105

VL - 8

SP - 402

EP - 409

JO - Annals of Family Medicine

JF - Annals of Family Medicine

SN - 1544-1709

IS - 5

ER -